Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof
The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
1. A method for diagnosing a human as being responsive to HMG-CoA reductase inhibitor treatment for reducing their risk for myocardial infarction (MI), the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene KIF6 as represented by position 101 of SEQ ID NO:18 or its complement by contacting said nucleic acid with an oligonucleotide comprising SEQ ID NO: 173;
b) detecting the presence of G at said position 101 of SEQ ID NO:18 or C at said complement; and
c) diagnosing said human as being responsive to HMG-CoA reductase inhibitor treatment for reducing their risk for MI due to the presence of said G or said C.
2. The method of claim 1 , wherein said method comprises nucleic acid amplification by polymerase chain reaction (PCR).
3. The method of claim 1 , wherein said detecting the presence of said G or said C comprises detecting the presence of an amplicon.
4. The method of claim 1 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
5. The method of claim 1 , wherein said human is homozygous for said G or said C.
6. The method of claim 1 , wherein said human is heterozygous for said G or said C.
7. The method of claim 1 , wherein said HMG-CoA reductase inhibitor treatment comprises an HMG-CoA reductase inhibitor selected from the group consisting of atorvastatin, rosuvastatin, pravastatin, simvastatin, fluvastatin, and lovastatin.
8. The method of claim 1 , further comprising administering an HMG-CoA reductase inhibitor to said human.
9. The method of claim 8 , wherein said HMG-CoA reductase inhibitor is selected from the group consisting of atorvastatin, rosuvastatin, pravastatin, simvastatin, fluvastatin, and lovastatin.
10. A method for diagnosing a human as being responsive to HMG-CoA reductase inhibitor treatment for reducing their risk for myocardial infarction (MI), the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene KIF6 as represented by position 101 of SEQ ID NO:18 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to G at said position 101 of SEQ ID NO:18 or C at said complement, wherein the nucleotide sequence of said oligonucleotide consists of a segment of at least 12 contiguous nucleotides of SEQ ID NO:18 or its complement and includes said position 101;
b) detecting the presence of said G or said C;
c) diagnosing said human as being responsive to HMG-CoA reductase inhibitor treatment for reducing their risk for MI due to the presence of said G or said C; and
d) administering an HMG-CoA reductase inhibitor to said human.
11. The method of claim 10 , wherein said oligonucleotide is an allele-specific probe.
12. The method of claim 10 , wherein said oligonucleotide is an allele-specific primer.
13. The method of claim 12 , wherein said allele-specific primer has a nucleotide sequence comprising SEQ ID NO:173.
14. The method of claim 10 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
15. The method of claim 10 , wherein said human is homozygous for said G or said C.
16. The method of claim 10 , wherein said human is heterozygous for said G or said C.
17. The method of claim 10 , wherein said HMG-CoA reductase inhibitor which is administered to said human is selected from the group consisting of atorvastatin, rosuvastatin, pravastatin, simvastatin, fluvastatin, and lovastatin.
18. The method of claim 10 , wherein said method comprises nucleic acid amplification by polymerase chain reaction (PCR).